Drugs Made In America Acquisition Corp
DMAABuild a strategy around DMAA
Drugs Made In America Acquisition Corp AI Insights
Informational only. Not investment advice.Snapshot
- Zero revenue SPAC with 237.6M in assets - 99.99% held in trust (717 cash). Trading at 1.51x book value despite no operating business.[Total Assets]
- Net income of 2.2M entirely from interest income (2.4M) on trust assets - no operational value creation.[Interest Income]
- Negative working capital (-428K) with only 717 in cash outside trust - severe liquidity constraint for deal execution.[Working Capital]
Watch Triggers
- P/B Ratio: Falls below 1.1x — Approaching NAV creates risk-adjusted entry with redemption floor protection
- Cash and Equivalents: Rises above 1M without dilution — Signals sponsor support or imminent deal announcement
- Volume: Spikes above 50K (50x current) — Unusual activity often precedes material announcements in SPACs
Bull Case
Clean balance sheet with zero debt (0.0 D/E) and 230.3M equity provides full downside protection at NAV redemption.
Pharma-focused mandate (Drugs Made In America) targets high-value sector with potential for premium deal multiples.
Bear Case
51% premium to NAV creates asymmetric downside - buying at 10.38/share vs 6.87 redemption value risks 34% loss on deal failure.
717 cash outside trust is critically low - cannot fund due diligence or extensions without dilutive financing.
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage DMAA's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
SPAC premium will compress toward NAV (~6.87/share) absent deal announcement within 12 months
- Current 51% premium to book unsustainable for pre-deal SPAC
- Near-zero operating cash (717) limits extension options
- SPAC market sentiment remains weak
Valuation Context
Caveats
DMAA Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$357.4M | — | ||
$357.49M | — | ||
53 | — | ||
$0 | — | ||
$0.20 | — | ||
0% | — | ||
0% | — | ||
$-379,193 | — | ||
2.89% | — | ||
Beta 5Y (Monthly) | unknown | — |
DMAA Dividend History
DMAA Stock Splits
DMAA SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
05/14/26 | 03/31/26 | 10-Q | |
04/15/26 | 12/31/25 | Unknown | |
11/18/25 | 09/30/25 | 10-Q | |
08/14/25 | 06/30/25 | 10-Q | |
05/20/25 | 03/31/25 | 10-Q | |
01/29/25 | 09/30/24 | 424B4 | |
09/30/24 | 09/30/24 | 424B4 | |
06/30/24 | 06/30/24 | S-1 |